Illumina, Inc. (NASDAQ: ILMN) today unveiled an 18-month roadmap of innovations that enhance the power and value of the ...
Cambridge Cluster life science game changer Syndex Bio is in Florida this week unveiling its proprietary mcPCR™ ...
Shares in the company lost about half their value in Friday trading after use of the test wasn’t associated with a statistically significant reduction in late-stage cancer diagnoses.
Grail’s stock was the Nasdaq’s biggest loser Friday, after a key trial of its Galleri early-detection cancer test failed to ...
Grail continues facing significant challenges as its stock plummeted over 45% after its landmark NHS-Galleri trial failed to ...
Prices rose 0.4% in December from the previous month, up from 0.2% in November, the Commerce Department said Friday in a ...
The renewed and expanded agreements provide improved commercial conditions, including more competitive pricing, optimized contractual terms, and enhanced supply security. These improvements will ...
Element Biosciences created a high-throughput benchtop device that can deliver a whole genome for $100 – half the price of ...
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the fourth quarter and full year 2025 ...
What is the Market Size of Precision Medicine Research and Development Platform? The global market for Precision Medicine ...
Zacks Investment Research on MSN
Why Illumina (ILMN) is a top value stock for the long term
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
The human genome is made up of 3 billion letters of DNA (A, T, C and G). Whole genome sequencing is a technique that is used ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results